Investigational drug · Phase 2
JNJ-88545223
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Arthritis, Psoriatic.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "JNJ-88545223"
First trial start
2026
Jan 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-88545223", any sponsor or status.
Conditions studied
As listed on its trial records.
- Arthritis, Psoriatic
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-88545223" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07321873 · 157 participants · Start Jan 15, 2026 · Primary completion Jun 28, 2027
Drug: JNJ-88545223; Placebo · For: Arthritis, Psoriatic
Sites: Searcy, Arkansas; Huntington Beach, California; San Diego, California · 75 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Arthritis, Psoriatic
- SonelokimabPhase 37 trials
MoonLake Immunotherapeutics AG · Hidradenitis Suppurativa, Arthritis, Psoriatic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.